Vancomycin Resistance Test

Most people only learn about vancomycin resistance when they or a family member end up in the hospital and a routine antibiotic stops working. By that point, the resistant bacteria have usually been living in the gut for months or years, quietly waiting for the right opportunity. This stool test looks for those resistance genes directly, so you can know what is in your microbiome before it ever becomes a clinical problem.

Vancomycin is reserved for serious infections caused by Gram-positive bacteria, including some forms of sepsis, bone infections, endocarditis, and severe Clostridioides difficile colitis. When gut bacteria carry resistance genes, those genes can transfer to other bacteria during an infection and make standard treatment fail. Knowing your status now is most useful if you are about to undergo a transplant, major surgery, cancer treatment, or any prolonged hospital stay.

What This Test Actually Detects

This test does not measure something your body produces. It measures DNA from bacteria in your stool, looking for the cluster of resistance genes known as the van gene family. The most clinically important members are vanA and vanB, which appear in vancomycin-resistant enterococci (VRE), a group of gut bacteria. Related genes (vanC, vanD, vanG, vanL, vanN) can also appear in other gut microbes, including some commensal anaerobes that act as a hidden reservoir.

When these genes are present, bacteria can rebuild the outer wall of their cells in a way that vancomycin can no longer grab onto. The drug essentially loses its target. The test does not tell you that you have an active infection. It tells you whether your gut microbiome is already carrying the genetic toolkit that would let resistant bacteria thrive if you were ever treated with vancomycin.

Why Resistance Genes in Your Gut Matter

Carrying VRE in your gut is not the same as being sick from it. The concern is what happens next. In a specialized infectious disease hospital, patients with rectal VRE colonization had roughly 10 times the risk of going on to develop a VRE bloodstream infection compared with non-colonized patients. A separate retrospective cohort showed that a prior positive VRE swab predicted vancomycin resistance in later sterile-site infections with 70% sensitivity and 97% specificity, with a positive likelihood ratio of 28.

Translation: if you are colonized and you do develop a serious enterococcal infection, the odds that the bacterium will resist vancomycin are very high. That single piece of information, known in advance, can steer your team toward linezolid or daptomycin from the first dose instead of losing days on a drug that will not work.

The Hospital and Bloodstream Infection Picture

Across European bloodstream infections, the share of Enterococcus faecium that was vancomycin-resistant more than doubled between 2012 and 2018, climbing from 8.1% to 19.0%, with the steepest increases in adults, the elderly, and inpatients. In Australian children, vancomycin-resistant E. faecium accounted for 25.5% of E. faecium bloodstream infections. German hospitals report E. faecium resistance above 20%, while Dutch hospitals stay below 1%, a contrast driven by infection control practices and antibiotic use rather than biology.

What this means for you: VRE is not a rare tropical curiosity. In many high-income healthcare systems, between one in five and one in four serious E. faecium infections will not respond to first-line vancomycin. That is the population-level reason to know what you are carrying.

Mortality Risk When Vancomycin Stops Working

Three independent meta-analyses agree on the direction of risk, even if the size varies. A pooled analysis of 9 adjusted studies covering 1,614 enterococcal bloodstream infections found that vancomycin resistance was linked to roughly 2.5 times higher odds of death (adjusted odds ratio 2.52, 95% CI 1.9 to 3.4). A second meta-analysis covering 13 studies in the era of effective alternative therapies still found about 80% higher odds of in-hospital death with VRE versus susceptible infections (odds ratio 1.80, 95% CI 1.38 to 2.35) and about five extra hospital days. A third, more recent meta-analysis covering 57 studies put the relative risk of death at 1.46 (95% CI 1.17 to 1.82) for E. faecium bloodstream infections.

The picture is not uniform. A Danish nationwide cohort of 6,071 enterococcal bloodstream infections found no excess 30-day mortality after adjusting for age, sex, and comorbidity (hazard ratio 1.08, 95% CI 0.90 to 1.29). Other large cohorts show that severity of illness and the species itself often dominate over the resistance status. The honest reading is that vancomycin resistance is a marker of a sicker, more complex clinical context, and in many settings it independently predicts worse outcomes, but its causal contribution depends on how quickly effective therapy is started.

Reference Ranges

There is no standardized cutpoint for gut-based vancomycin resistance gene testing the way there is for cholesterol or HbA1c (a measure of long-term blood sugar). This is a research-grade test reported as detected or not detected, sometimes with a relative abundance estimate. The ranges below describe what each result pattern signals based on published colonization and infection studies.

Note on lab variability: stool-based resistance gene assays differ in which genes they target, the DNA extraction method, and the detection threshold. Compare your results within the same lab over time rather than treating any single result as a universal absolute.

Tracking Your Trend

A single result tells you a snapshot. Your gut resistance gene profile can shift after antibiotics, hospitalization, travel, and even close contact with colonized household members. In a randomized trial in patients with cirrhosis, fecal microbiota transplant reduced or prevented expansion of vancomycin resistance genes including vanH, while placebo recipients on standard care showed gradual increases over time.

A practical cadence: get a baseline now, especially if you are healthy and proactive. Retest 3 to 6 months after any course of broad-spectrum antibiotics or any hospital admission longer than a few days. If your baseline is positive, retest every 6 to 12 months to see whether your microbiome is clearing the genes or holding onto them. If you have a planned procedure (transplant, major surgery, prolonged immunosuppression), retest within 4 to 8 weeks beforehand so your team has current information.

When Results Can Be Misleading

• Recent antibiotics: a 5-day course of broad-spectrum antibiotics (such as metronidazole, amoxicillin, or ciprofloxacin) can transiently expand vancomycin resistance genes in the gut, peaking around day 7 and partially reverting by day 15. Testing during or just after a course can overstate your steady-state risk.
• Sample collection: stool DNA tests are sensitive to how the sample is collected and stored. Samples that sit at room temperature for too long, get contaminated with toilet water, or come from only one part of a bowel movement may miss low-abundance resistance genes.
• Detection threshold differences: each lab uses a different cutoff for what counts as detected. A negative result on a less sensitive assay does not always mean zero genes are present, just that they are below the lab's threshold.
• Recent travel or hospitalization: a few days of carriage acquired in a hospital or while traveling internationally can show up as a positive result that may or may not persist. A repeat test 4 to 8 weeks later helps distinguish transient pickup from established colonization.

What an Abnormal Result Should Make You Do

A positive result is not an emergency, and there is no treatment that reliably eradicates VRE from the gut. What it does change is the playbook your medical team uses if you ever need antibiotics for a serious infection. Add the result to your medical record so any future hospital team sees it on admission. If you are heading into a high-risk situation (chemotherapy, transplant, major abdominal surgery, ICU stay), share the result with your specialist so empiric coverage can include linezolid or daptomycin from the start rather than losing days on vancomycin.

Pair this test with a calprotectin test (a marker of gut inflammation) and a broader gut microbiome panel if you want a fuller picture of your gut health. If you have a history of recurrent C. difficile infections, frequent hospitalizations, or known immunosuppression, an infectious disease specialist or a gastroenterologist familiar with the microbiome is the right person to interpret the trend with you. For most healthy people, an annual recheck and a retest after any antibiotic course is enough to track your trajectory.